Literature DB >> 15581271

Effects of lipopolysaccharide on the appearance of macrophage populations and fibrogenesis in cisplatin-induced rat renal injury.

Jyoji Yamate1, Yuuko Machida, Mika Ide, Mitsuru Kuwamura, Osamu Sawamoto, Jonathan LaMarre.   

Abstract

Macrophages play an important role in renal interstitial fibrosis via production of transforming growth factor-beta1 (TGF-beta1) and tumor necrosis factor-alpha (TNF-alpha); these fibrogenic factors mediate induction of myofibroblastic cells capable of producing extracellular matrices. We investigated the effects of lipopolysaccharide (LPS), a macrophage activator, on the appearance of macrophage populations and subsequent fibrogenesis in cisplatin (CDDP)-induced rat renal lesions. In keeping with the progression of interstitial fibrosis, alpha-smooth muscle actin (alpha-SMA)-immunopositive myofibroblastic cell number began to increase on day 4 and continued gradually until day 16 after CDDP injection. Cells immunoreactive for ED1 (for exudate macrophages), ED2 (for resident macrophages) and ED3 (for activated resident macrophages) showed the highest number on day 4 or day 7, and thereafter, the numbers were gradually decreased up to day 16. On the other hand, the number of cells immunoreactive for OX6 (rat MHC class II-recognizing antibody) was increased on day 7 and remained elevated up to day 16. LPS was injected on day 7 after CDDP injection when the greatest number of ED1-positive macrophages were present. In CDDP/LPS-injected rats, the numbers of macrophages reacting to ED1, ED2, ED3, and OX6 were higher than those in CDDP-injected rats during the observation period between days 7 and 16; ED3- and OX6-positive cells were more prominently increased than ED1- and ED2-postive cells. By RT-PCR analysis, the expression of TGF-beta1 and TNF-alpha mRNAs in CDDP/LPS-injected rats on day 7 was markedly increased in contrast to those in CDDP-injected rats. These findings indicate that LPS treatment enhanced the macrophage expression of fibrogenic factors. However, there was no marked difference in the fibrogenesis between CDDP/LPS- and CDDP-injected rats. These findings suggest that the macrophage populations appearing in CDDP-induced rat renal lesions should be investigated further, to address the complicated pathogenesis of renal interstitial fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15581271     DOI: 10.1016/j.etp.2004.04.008

Source DB:  PubMed          Journal:  Exp Toxicol Pathol        ISSN: 0940-2993


  6 in total

1.  Nephroprotective effect of bee honey and royal jelly against subchronic cisplatin toxicity in rats.

Authors:  Abdelazim Ibrahim; Mabrouk A Abd Eldaim; Mohamed M Abdel-Daim
Journal:  Cytotechnology       Date:  2015-02-27       Impact factor: 2.058

2.  Nephroprotective efficacy of ceftriaxone against cisplatin-induced subchronic renal fibrosis in rats.

Authors:  Mohamed M Abdel-Daim; Yasser S El-Sayed; Mabrouk Abd Eldaim; Abdelazim Ibrahim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-14       Impact factor: 3.000

3.  Comparative nephrotoxicity of Cisplatin and nedaplatin: mechanisms and histopathological characteristics.

Authors:  Takeki Uehara; Jyoji Yamate; Mikinori Torii; Toshiyuki Maruyama
Journal:  J Toxicol Pathol       Date:  2011-06-30       Impact factor: 1.628

4.  Oxytocin alleviates cisplatin-induced renal damage in rats.

Authors:  Oytun Erbas; Huseyin Anil Korkmaz; Fatih Oltulu; Hüeyin Aktug; Altug Yavasoglu; Levent Akman; Volkan Solmaz; Dilek Taskiran
Journal:  Iran J Basic Med Sci       Date:  2014-10       Impact factor: 2.699

5.  Immunophenotypical Characterization of M1/M2 Macrophages and Lymphocytes in Cisplatin-Induced Rat Progressive Renal Fibrosis.

Authors:  Minto Nakagawa; Mohammad Rabiul Karim; Takeshi Izawa; Mitsuru Kuwamura; Jyoji Yamate
Journal:  Cells       Date:  2021-01-28       Impact factor: 6.600

Review 6.  Sialoadhesin - a macrophage-restricted marker of immunoregulation and inflammation.

Authors:  Alexander S G O'Neill; Timo K van den Berg; Gregory E D Mullen
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.